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ABSTRACT
Objective: The aim of this study was to evaluate the efficacy of 
combined treatment with anti-tumor necrosis factor (TNF) agents, 
and setons for perianal fistulas in Crohn’s disease.
Patients and Methods: Study included 27 consecutive patients 
with perianal fistulizing Crohn’s disease, requiring seton drainage 
and anti-TNF therapy in our center from January 2013 to November 
2014. All patients underwent a standardized pelvic magnetic 
resonance imaging (MRI) examination. Patient characteristics, 
follow up time, findings of pelvic MRI, colonoscopy and 
examination under anesthesia findings were recorded. Response to 
treatment was evaluated at the end of the follow up.
 Results: The median follow-up after treatment was 17 months 
(6-32). The fistula was complex in 24 (89%) of the 27 patients. 
Colonoscopy revealed ileitis in 16 (59.3%) patients and active 
proctitis in 9 (33.3%) patients. Perianal abscess was observed in 
12 (44.4%) patients. Complete response was obtained in 17 (63%) 
patients. Only 3 (11.1%) patients experienced recurrence abscess 
during the study period. We could not find any factor, which were 
associated with complete response. 
Conclusion: Complete response was achieved in 63% of the 
patients, with perianal fistula formation associated with Crohn’s 
disease, with combined seton drainage and anti-TNF therapy. 
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ÖZ
Amaç: Bu çalışmanın amacı perianal Crohn hastalığında, kombine 
seton ve anti tümör nekroz faktörü (TNF) ajanlarla yapılan 
tedavinin etkinliğini değerlendirmektir. 
Hastalar ve Yöntem: Ocak 2013 ve Kasım 2014 tarihleri 
arasında kombine seton drenaj ve anti-TNF tedavisi uygulanmış 
ardışık 27 perianal fistülizan Crohn hastası çalışmaya dahil edildi. 
Tüm hastalar standart pelvik manyetik rezonans görüntüleme 
(MRG) ile incelendi. Hasta özellikleri, takip zamanı, pelvik MRG 
bulguları, kolonoskopi ve genel anestezi altında rektal muayene 
bulguları, kaydedildi. Takip süresinin sonunda tedaviye yanıt 
değerlendirildi. 
Bulgular: Tedavi sonrası ortanca takip süresi 17 (6-32) ay idi. 
Hastaların 24 (%89)’ünde fistül kompleks yapıda idi. Kolonoskopi 
bulgularına göre 16 (%59,3) hastada ileit, 9 (%33,3) hastada aktif 
proktit saptandı. On iki (%44,4) hastada perianal apse gözlendi. 
Tedaviye tam yanıt 17 hastada elde edilirken, çalışma sürecinde 
sadece 3 (%11,1) hastada tekrarlayan perianal apse ile karşılaşıldı. 
Değerlendirdiğimiz faktörlerden hiçbiri komplet yanıt ile anlamlı 
olarak ilişkili bulunmadı.  
Sonuç: Crohn hastalığı ile ilişkili kompleks perianal fistülde 
kombine seton ve anti-TNF tedavi ile hastaların % 63’ünde 
tedaviye tam yanıt sağlanmıştır. 
Anahtar kelimeler: Crohn hastalığı, Perianal fistül, Seton, 
Infliximab
Introduction
Perianal fistulas occur in 23-26 % of patients with Crohn’s 
disease (CD) and can cause significant morbidity [1]. 
Patients with perianal fistulas can present with symptoms 
such as constant anal pain, especially in post-defecation, 
swelling around the anus, malodourous discharge of pus 
and/or blood from the external opening with skin irritation 
around the anus, fever, and even incontinence [2]. Contrary 
to cryptoglandular origin; the formation of perianal fistulas 
in CD is based on the presence of a penetrating ulcer in the 
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rectal or anal mucosa, resulting in an abnormal granulating 
connection between the epithelial lining of the rectum or 
anal canal and the perianal skin [3.4].
  Pelvic magnetic resonance imaging (MRI) is accurate in 
determining the exact location of the fistula, differentiating 
between a fibrotic and septic fistula and locating abscesses 
[5]. Anorectal endoscopic ultrasound (EUS) is equivalent 
to pelvic MRI, with less cost, but it requires expertise [6]. 
Examination under anesthesia (EUA) has the advantage of 
the possibility of concomitant drainage of abscesses and 
placement of non-cutting setons. The random combination 
of two of three methods (MRI, EUS and EUA) resulted in 
a 100% correct classification of perianal fistulizing Crohn’s 
disease (PFCD) [7].
Perianal fistulas are classified according to Parks 
classification [8]; this is also useful for CD, although more 
complicated tracts can occur in a CD patient. Furthermore, this 
system does not include other perianal manifestations of CD 
(e.g. abscesses or strictures). According to the classification 
of the American Gastroenterological Association (AGA) 
[4] a simple anal fistula is defined as having a single low 
transsphincteric track without abscess formation, stenosis 
or anorectal inflammation. All other forms are classified as 
complex and comprise the majority of lesions.
The treatment of PFCD is based on surgical fistula 
drainage, fecal diversion, antibiotics, immunosuppressant 
drugs, and anti- tumor necrosis factor (TNF) agents. All 
fistulas are potential sources of sepsis; therefore, obtaining 
drainage is fundamental in all locations to prevent abscess 
formation. Since anal continence mechanism may be 
damaged, perineal interventions have limited role. In the 
case of perianal fistulas, non-cutting loose seton drainage 
is the method of choice to prevent recurrent abscesses and 
anal continence. The timing of the removal of seton drains 
varies between centers, as controlled data are lacking [9]. 
Surgical diversion of the fecal stream by a stoma often 
allows healing; however, many patients find a stoma to be 
undesirable, and the benefit of this approach is unlikely to 
maintain after bowel continuity is restored [10].
Perianal fistulizing Crohn’s disease is accepted as an 
indication of therapy with a monoclonal chimeric antibody to 
TNF-a: infliximab. The effectiveness of this treatment has been 
established first by Present et al. [11] and then confirmed in the 
ACCENT II trial [12]. Another anti-TNF agent, adalimumab 
is also shown as an efficacious and safe treatment for PFCD in 
patients who have failed infliximab treatment [13]. 
The optimal clinical approach in the treatment of PFCD, 
however, has yet to be defined, and a satisfactory treatment 
algorithm is lacking. The aim of this study was to evaluate 
the efficacy of combined treatment with anti-TNF agents 
and setons for PFCD.
Patients and Methods
Our study included 27 consecutive PFCD patients requiring 
seton drainage and anti-TNF therapy in a tertiary center 
from January 2013 to November 2014. We excluded 
patients who had a follow-up of less than 6 months. A 
written informed consent was obtained from all patients who 
had participated study. A retrospective analysis of collected 
data from medical files was performed to describe. Patient’s 
characteristics, demographic data, pelvic MRI, colonoscopy 
and EUA findings (number, type, and location of fistulas 
tracts, presence or not of abscess), response to therapy were 
noted from medical files, and analyzed retrospectively. 
All patients underwent a standardized pelvic MRI 
examination with a 1.5 Tesla magnetic resonance imaging 
system (Magnetom Symphony; Siemens, Munich, 
Bavaria, Germany) with use of an intravenous contrast 
agent. Gastrointestinal radiologists evaluated the images 
and a detailed report was created including the amount 
of fistulas (single, single branched, or multiple), location 
(extrasphincteric, intersphincteric, transsphincteric, or 
suprasphincteric), extension (supra or infralevatoric), 
presence of a collection, and rectal wall involvement 
(normal, thickened).
All patients underwent surgical drainage of abscess (when 
existent) and seton placement, accompanied by a 2-week 
course of antibiotics (metronidazole and/or ciprofloxacin), 
and followed by infliximab induction treatment (three i.v.; 
administrations at 5 mg/kg at week 0, week 2, and week 
6). Seton removal was planned when fistulous output 
was reduced after third infliximab injections. A patient 
was considered as a responder in the absence of drainage 
from all fistulas despite gentle finger compression with 
or without cicatrisation of the external fistula orifice [12]. 
Factors were investigated, such as age, gender, CD duration, 
ileitis, proctitis, perianal abscess, fistula multiplicity, type of 
fistula, and follow up time, which may affect the response of 
combined therapy on PFCD. 
Statistical Analysis
For each, data median and range were calculated. Comparison 
of patients according to the response to combined treatment 
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was made by Chi square test or Fisher’s Exact test for 
qualitative and by Student’s t-test or Mann Whitney U test 
for quantitative variables. Data were analyzed using SPSS 
(SPSS Inc., Chicago, IL, USA) for Windows, version 17. 
All tests were two-sided and p-values below 0.05 were 
considered statistically significant.
Results
This study included 27 consecutive patients with PFCD 
requiring seton drainage and anti-TNF therapy in our center 
from January 2013 to November 2014. The median age of 
the study cohort was 38 years (20-70) and 17 (63%) were 
male patients. 
The first symptom of CD was perianal fistula in 6 (22.2%) 
patients. Fistula was diagnosed in the other 21 patients at 
median time of 5.5 (1-30) years after the diagnosis of CD. 
Median follow up time for the study cohort was 17 (6-32) 
months. 
Colonoscopy before seton insertion revealed ileitis in 16 
(59.3%) patients and active proctitis in 9 (33.3%) patients. 
Only one patient exhibited both conditions. Perianal abscesses 
were observed in 12 (44.4%) patients. Pelvic MRI before 
treatment revealed the median number 1 (1-4) of fistulas (Table 
I). Total amount of fistulas, which were detected with MRI 
were 41 in 27 patients. The majority (70.7%) of the fistulas 
were transsphincteric and suprasphincteric (Table II). Four 
(14.8%) patients had horseshoe fistula. According to (AGA) 
classification 3 (11.1%) had simple while 24 (88.9%) had 
complex fistula.
Table I. Patients’ characteristics
Age 38    (20-70)
Gender 
    Male
    Female
17     (63%)
10     (37%)
Duration between CD diagnosis 
and PFCD (year)
5.5    (1-30)
Number of fistulas (MRI)
    
                          1
2
3
4
Median number of fistulas
17     (63 %)
6       (22 %)
2       (7 %)
1       (4 %)
1       (1-4)
Perianal abscess 12     (%44.4)
Proctitis 9       (%33.3) 
Ileitis 16     (%59.3)
CD: Crohn’s Disease, PFCD: Perianal Fistulizing Crohn’s 
Disease, MRI: Magnetic Resonance Imaging
Table II.  Types of fistula according to MRI results
 N  (%)
Intersphincteric 10  (24.4)
Transsphincteric 19  (46.3)
Suprasphincteric   7  (17.1)
Extrasphincteric   1  (2.4)
Horseshoe   4  (9.8)
Total fistula number (27 patients) 41  (100)
Twenty-one (77.7%) patients were treated with 
infliximab, because of drug intolerance or resistance, 
and six (22.2%) patients were treated with adalimumab. 
Nineteen patients (70.4%) had an initial response at week 
6 after the third injection of anti-TNF agent. Setons were 
removed in 10 (37%) patients. Only 3 (11.1%) recurrent 
perianal abscesses were observed during follow up period. 
Two of these patients had abscesses at eighteen and nineteen 
months after initial response and seton removal. They were 
successfully treated with repeat drainage, seton replacement 
and anti-TNF agents. Among 17 (63%) patients who are 
still have seton only one patient developed recurrent abscess 
during follow up. Diverting colostomy was performed for 
this patient. 
After combined therapy of anti-TNF agents and seton 
insertion, a complete response was obtained in 17 (63%) 
patients by the end of the study period. When patients with 
clinical response were compared to those without, there 
were not any significant difference between the two groups 
regarding age, gender, CD duration, ileitis, proctitis, perianal 
abscess, fistula multiplicity, type of fistula, and follow up 
time (Table III). 
Table III. Comparing the characteristics of the patients according 
to the outcome of the treatment
Variable Responder 
patients
(n= 17)
No responder 
patients       
(n= 10)
P value
Age (year) 38    (20-70) 34   (20-55) 0.45
Gender
             Male
             Female
 
11    (65%)
  6     (35%)
 
6    (60%)
4    (40%) 1
CD duration (year)   4     (0-30) 3    (0-14) 0.84
Ileitis 10     (59%) 6    (60%) 1
Proctitis   6     (35%) 3    (30%) 1
Perianal abscess   7     (41%) 5    (50%) 0.71
Fistula multiplicity   6     (35%) 3    (30%) 0.78
Type of fistula 
(AGA classification)
          Simple
          Complex
 
 
 2     (14%)
15    (88%)
 
 
1    (10%)
9    (90%) 1
Follow up time 17    (3-29) 8    (3-27) 0.24
CD: Crohn’s Disease, AGA:American Gastroenterological 
Association 
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Discussion
Achieving rapid and sustained fistula healing is challenging 
in CD patients. Choosing criteria of complete response is 
important because radiologic response rates, as previously 
reported, are not at a level high enough to evaluate treatment. 
Radiologic healing of PFCD was achieved in only one 
quarter of the patients with clinical response [14]. Present et 
al., defined a complete response in PFCD means absence of 
drainage from all fistulas with or without cicatrisation of the 
external fistula orifice [11]. Almost all studies about PFCD 
have used the Present’s criteria for complete response. 
Seton drainage combined with infliximab treatment 
has shown promising results. The ACCENT II trial, which 
is a cornerstone study about PFCD treatment, has shown 
that infliximab treatment is superior to a placebo. The 
initial response was 64%, however complete response rate 
decreased to 36% in 54 weeks [12]. In similar fashion; 
Haennig et al., recently reported initial response and 
complete response rates as 88 % and 75% respectively 
[15]. This was related with late recurrences, which were 
unnoticed in early periods of treatment. In our study, initial 
response rate was 70.4%. Only two patients experienced 
recurrences near 1.5 years after their initial response. These 
two patients were accepted as non-responders, although 
they had complete response after second seton insertion and 
anti-TNF treatment. Clinicians and patients should be aware 
of late recurrences, because perianal abscess may be even 
mortal in an immune compromised patient unless urgent 
drainage is done. 
Studies, which investigated the results of combined seton 
and anti-TNF treatment for PFCD, reported a great range of 
complete response rate between 18-75% (Table IV) [11, 12, 
15-24]. Table IV was meticulously prepared only for PFCD. 
Patients with other manifestations of CD or undergone other 
treatment modalities were extracted as much as possible. 
This discrepancy of the results may be related with varied 
follow up times, heterogeneity and extent of CD and other 
local or systemic immunosuppressive agents used. A 63% 
complete response rate, achieved in our study, is acceptable 
for a 17-month follow up time. 
In 20–45% of the CD patients a perianal fistula developed 
before or at the time of CD diagnosis [1]. Consistently, the 
first presentation was perianal fistula in 6 (22.2%) patients in 
our series. The combination of two of three methods (MRI, 
EUS and EUA) is recommended for correct classification of 
PFCD. Pretreatment MRI showed that the most common type 
of fistula in PFCD is transsphincteric fistula. It is compatible 
with previous studies [7]. Preoperative characterization of 
PFCD is important, because an overlooked fistula tract can 
cause treatment failure during EUA. In our opinion, surgeon 
would be aware of complex or multiple fistulas owing to 
preoperative MRI, and it indirectly increases the success of 
the treatment. 
Table IV. Some of the previous studies investigating the efficacy 
of combined seton and infliximab treatment 
Year Author Number 
of 
patients 
(N)
Follow 
up time 
(months)
Complete 
response 
rate (%)
1999 Present et al. [11]  56     3  46
2003 Topstad et al. [16]  29     9  29
2004 Sand et al. [12]  89    13  36
2005 Talbot et al. [18]  21    20  47
2006 Hyder et al. [19]  22    21  18
2008 Guidi et al. [20]    9    19  55
2009 Tougeron et al. [17]  28    58  42
2009 Bouguen et al. [21]  31    43  54
2012 Duff et al. [22]  52    66  42.3
2013 Antakia et al. [23]  48    20  29
2013 Bouguen et al. [24]  97    55  60
2015 Haennig et al [15]  81    64  75
Present study  27    17  63
The best time for removal of the seton is controversial 
[9]. An early seton removal may increase the risk of perianal 
infection because of inadequately drained collection during 
anti-TNF treatment. On the other hand, prolonged stay 
can result in maturation of the fistulous track, leading 
to persistence incapability to heal after seton removal. 
Although it is widely believed that setons protect the patients 
from perianal abscess, we observed recurrence abscess in 
one patient with seton. Only this patient (3.7%) required 
diverting stoma. In our opinion, removal of the setons needs 
to be considered after infliximab infusion based on both 
clinical and MRI evaluation of perianal region.
Female gender, complex fistula formation, active 
intestinal and rectal diseases were reported as factors 
independently associated with failure of combined treatment 
[16, 17]. Any factor, which significantly related to complete 
response, could not be found in the study. This could 
be due to relatively small size of this study and/or great 
heterogeneity of PFCD patients.
This study has some limitations in need of 
acknowledgment. First, this was a retrospective study and 
does not have control arm, and study includes a small number 
of patients for evaluating the previous known predictors. 
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Second, seton removal time is not standard but based on 
clinical response. This study does not include information 
about optimal seton removal time. 
In conclusion, we reported a group of PFCD patients 
treated with seton drainage and anti-TNF agents with 
63% complete response rate in 17 month follow up time. 
Although, a high rate of complete response has been 
achieved in this study, a considerable rate of patients (37%) 
did not respond well to the current treatment. New or 
additional treatment modalities should be investigated with 
randomized controlled studies in the future. 
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